Common (>10% users at bodybuilder doses):

• Atherogenic lipid changes — HDL drops 30-60% within 4-6 weeks; LDL rises; ApoB rises. The most universally reported objective side effect on bloodwork. Turinabol is among the worst AAS for HDL because of the non-aromatizable + DHT-pattern + 17α-alkylated combination.
• HPG suppression — testicular atrophy (mild-to-moderate), reduced endogenous testosterone, low LH/FSH; recovery typically 4-12 weeks post-cycle without PCT, faster with PCT
• Hepatotoxicity (transaminitis) — ALT/AST elevation, dose-dependent; typically reversible on cessation; monitor at week 3-4 for any 6+ week cycle
• Mild libido changes (initially up, later down as HPG suppression takes hold)
• Skin / hair changes (less than dianabol or testosterone but not zero) — mild acne, scalp hair shedding in genetically predisposed users
• Forearm / bicep "pumps" — transient, typical of DHT-pattern AAS

Less common (1-10%):

• Cholestatic jaundice — yellowing of skin / sclera, dark urine, pruritus; reversible on cessation
• Mood changes — mild irritability, occasional aggression; less than test or tren but reported
• Sleep disturbance in some users
• Hypertension — modest BP elevation, dose-dependent
• Erythrocytosis — mild hematocrit increase; less than testosterone esters
• Virilization in women — clitoral hypertrophy, voice deepening (may be irreversible), hirsutism, menstrual disruption — at low doses (5-10 mg/day) less severe than higher-androgenic AAS but real, especially with long-term use; the East German adolescent female cohort documents irreversible androgenization at sustained recreational-equivalent doses.

Rare-serious (<1% but documented in turinabol literature):

• Peliosis hepatis — cystic blood-filled hepatic lesions; documented case reports with chronic 17α-alkylated AAS use including turinabol; potentially life-threatening (hepatic hemorrhage)
• Hepatocellular adenoma / carcinoma — extremely rare but documented in long-term high-dose 17α-alkylated AAS exposure; the East German cohort produced multiple liver tumor case reports
• Severe atherogenic dyslipidemia + accelerated CVD — particularly with cumulative multi-cycle use; the East German cohort produced documented elevated cardiovascular morbidity at long follow-up
• Cardiomyopathy — extrapolated from broader AAS literature (Baggish 2017 Circulation cardiac MRI cohort); cumulative-exposure-dependent
• Severe HPG suppression with prolonged hypogonadism post-cycle — secondary hypogonadism failing to recover; risk rises with cycle length and individual susceptibility
• Mood crash / post-cycle depression — well-documented bodybuilding phenomenon and East German cohort follow-up; persistent anhedonia / low mood for weeks-to-months post-cycle in susceptible users; in the East German cohort, sustained depression was a reported long-term sequela

Specific watch periods:

• Week 3-4 of any cycle: ALT/AST + lipid panel — flag if ALT >3× ULN or HDL drops >50%
• End of cycle: Full HPG panel (T, LH, FSH, E2) to confirm degree of suppression
• Week 4-8 post-cycle: HPG recovery check; if still suppressed, formal PCT or endocrinology consult
• Multi-cycle users (years): Periodic echocardiogram, lipid trend tracking, liver imaging if any symptom

The "long-term metabolite" forensic risk (turinabol-specific): The M3 metabolite (~20βOH-NorDHCMT, formally 4α-chloro-17β-hydroxymethyl-17α-methyl-18-nor-5α-androstan-13-en-3α-ol) is detectable in urine for 9-12+ months post-use via Sobolevsky-Rodchenkov 2012 LC-MS/MS. This is uniquely catastrophic for any tested or potentially-tested athlete. The 2016 IOC reanalysis of Beijing 2008 + London 2012 stored samples produced approximately 80 retroactive AAFs, with cascading 8-year-old medal strippings hitting weightlifters and throwers from Russia, Belarus, Ukraine, and Kazakhstan particularly hard. For a 20yo MMA athlete with ANY plausible future in tested competition (even amateur state-level events with USADA-style testing), turinabol is uniquely poor risk — even a single 6-week cycle 12 months before a meet is detectable.